Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Pierre Chue & James Chue. (2012) A review of paliperidone palmitate. Expert Review of Neurotherapeutics 12:12, pages 1383-1397.
Read now
Read now
Natalie C. Edwards, Erik Muser, Dilesh Doshi & John Fastenau. (2012) The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving. Journal of Medical Economics 15:4, pages 623-634.
Read now
Read now
L Annemans, I Eijgelshoven, A Smet, A Jacobs & G Bergman. (2012) THE IMPACT OF TREATMENT WITH RISPERIDONE LONG-ACTING INJECTION ON THE BELGIAN HEALTHCARE SYSTEM: RESULTS FROM A BUDGET IMPACT MODEL. Acta Clinica Belgica 67:2, pages 108-119.
Read now
Read now
L Samalin, T Charpeaud, O Lorabi & PM Llorca. (2010) Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection. Patient Preference and Adherence 4, pages 325-334.
Read now
Read now
Ofer Agid, George Foussias & Gary Remington. (2010) Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opinion on Pharmacotherapy 11:14, pages 2301-2317.
Read now
Read now
Andrea Fagiolini, Francesco Casamassima, Wilmer Mostacciuolo, Rocco Forgione, Arianna Goracci & Benjamin I Goldstein. (2010) Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder. Expert Opinion on Pharmacotherapy 11:10, pages 1727-1740.
Read now
Read now
Articles from other publishers (19)
Todd A. Tishler, George Bartzokis, Po H. Lu, Erika P. Raven, Mher Khanoyan, Chandra J. Kirkpatrick, Meghan H. Pyle, J. Pablo Villablanca, Lori L. Altshuler, Jim Mintz, Joseph Ventura, Laurie R. Casaus, Kenneth L. Subotnik, Keith H. Nuechterlein & Benjamin M. Ellingson. (2018) Abnormal Trajectory of Intracortical Myelination in Schizophrenia Implicates White Matter in Disease Pathophysiology and the Therapeutic Mechanism of Action of Antipsychotics. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 3:5, pages 454-462.
Crossref
Crossref
Ruben Vardanyan. 2017. Piperidine-Based Drug Discovery. Piperidine-Based Drug Discovery
241
267
.
Azmi F. Nasser, David C. Henderson, Maurizio Fava, Paul J. Fudala, Philip Twumasi-Ankrah, Alex Kouassi & Christian Heidbreder. (2016) Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia. Journal of Clinical Psychopharmacology 36:2, pages 130-140.
Crossref
Crossref
Christopher M. Filley. 2016. White Matter Dementia. White Matter Dementia
142
152
.
Celine M. Laffont, Roberto Gomeni, Bo Zheng, Christian Heidbreder, Paul J. Fudala & Azmi F. Nasser. (2015) Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone. The Journal of Clinical Pharmacology 55:1, pages 93-103.
Crossref
Crossref
Sofia Brissos, Miguel Ruiz Veguilla, David Taylor & Vicent Balanzá-Martinez. (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology 4:5, pages 198-219.
Crossref
Crossref
Nam Young Lee, Se Hyun Kim, Seong Jin Cho, Young-Cho Chung, In Kwa Jung, Chang Yoon Kim, Duk Ho Kim, Dong Geun Lee, Yo Han Lee, Weon Jeong Lim, Young Suk Na, Sang Eun Shin, Jong-Min Woo, Jin Sang Yoon, Bo-Hyun Yoon, Yong Min Ahn & Yong Sik Kim. (2014) A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. International Clinical Psychopharmacology 29:5, pages 279-287.
Crossref
Crossref
O. Castellano, M. Arji, C. Sancho, J. Carro, A.S. Riolobos, V. Molina, R. Gmez-Nieto, Jos de Anchieta de Castro e HortaJr.Jr., M.J. Herrero-Turrin & D.E. Lpez. (2013) Chronic administration of risperidone in a rat model of schizophrenia: A behavioural, morphological and molecular study. Behavioural Brain Research 242, pages 178-190.
Crossref
Crossref
Evanthia Achilla & Paul McCrone. (2013) The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia. Applied Health Economics and Health Policy 11:2, pages 95-106.
Crossref
Crossref
Tetsuya Tanioka, Sakiko Sakamaki, Yuko Yasuhara, Masahito Tomotake, Kensaku Takase, Chie Watari, Kouichi Makiguchi, Rozzano Locsin, Kazushi Motoki & Tatsuya Inui. (2013) Optimal needle insertion length for intramuscular injection of risperidone long-acting injectable (RLAI). Health 05:12, pages 1939-1945.
Crossref
Crossref
Laura C. Blumberg, Tarek A. Zeidan, Adrian Maddaford, Nicole C. Warren & Panee Hutchison. (2013) Novel N-5-(acyloxyalkoxy)carbonyl prodrugs of olanzapine with physicochemical properties for extended-release. RSC Advances 3:37, pages 16270.
Crossref
Crossref
Eduard Vieta, Stuart Montgomery, Ahmad Hatim Sulaiman, Rodrigo Cordoba, Benedicte Huberlant, Lupe Martinez & Andreas Schreiner. (2012) A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. European Neuropsychopharmacology 22:11, pages 825-835.
Crossref
Crossref
George Bartzokis, Po H. Lu, Erika P. Raven, Chetan P. Amar, Nicole R. Detore, Alexander J. Couvrette, Jim Mintz, Joseph Ventura, Laurie R. Casaus, John S. Luo, Kenneth L. Subotnik & Keith H. Nuechterlein. (2012) Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophrenia Research 140:1-3, pages 122-128.
Crossref
Crossref
George Bartzokis. (2012) Neuroglialpharmacology: Myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology 62:7, pages 2137-2153.
Crossref
Crossref
Annie Viala, Françoise Cornic & Marie-Noëlle Vacheron. (2012) Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia. Schizophrenia Research and Treatment 2012, pages 1-5.
Crossref
Crossref
Aloys Prinz. 2012. Handbuch der Psychopharmakotherapie. Handbuch der Psychopharmakotherapie
563
574
.
Wayne Macfadden, Cherilyn DeSouza, Concetta Crivera, Chris M Kozma, Riad D Dirani, Lian Mao & Stephen C Rodriguez. (2011) Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. BMC Psychiatry 11:1.
Crossref
Crossref
George Bartzokis, Po H. Lu, Chetan P. Amar, Erika P. Raven, Nicole R. Detore, Lori L. Altshuler, Jim Mintz, Joseph Ventura, Laurie R. Casaus, John S. Luo, Kenneth L. Subotnik & Keith H. Nuechterlein. (2011) Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory. Schizophrenia Research 132:1, pages 35-41.
Crossref
Crossref
Jay Prakash Jain, Wubeante Yenet Ayen, Abraham J. Domb & Neeraj Kumar. 2011. Biodegradable Polymers in Clinical Use and Clinical Development. Biodegradable Polymers in Clinical Use and Clinical Development
1
58
.